Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HDM2005 in Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumors
NCT06615193Phase 1Recruiting
- Sponsor
- Huadong Medicine
- Start
- Aug 2024
- Primary completion
- Jun 2026
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HDM2005 in B cell lymphoma and solid tumor, sponsored by Huadong Medicine. Primary endpoints: Incidence of Dose Limiting Toxicity at 21 days, Incidence and Severity of Adverse Events and 2 more. Started Aug 2024; status: recruiting.
02
Drugs
HDM2005
03
Conditions
B cell lymphomasolid tumor
Beyond the preview
Go deeper on NCT06615193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06615193.